In 2024, the group achieved revenues of AED25.8 billion, EBITDA of AED4.1 billion and a net profit of AED1.7 billion
Abu Dhabi-based PureHealth announced today a proposal for its first-ever dividend distribution since listing on the Abu Dhabi Securities Exchange (ADX) in December 2023. The board of directors recommended a total dividend of AED343 million ($93.39 million), equivalent to AED3.09 fils per share, for the 2024 financial year. This represents 20 percent of the group’s net profit.
The proposal is set for shareholder approval at the annual general meeting on April 9, 2025. Following the announcement, PureHealth shares were trading 4.5 percent higher at AED3.01.
PureHealth achieves net profit of AED1.7 billion in 2024
This dividend follows the completion of PureHealth’s first full financial year as a publicly listed company. It highlights the strength of PureHealth’s balance sheet, its ability to generate returns for shareholders, and its capacity to grow the business while maintaining a robust capital position. The group noted that it will retain the remainder of the profits, providing financial flexibility to support future growth plans and potential global expansion opportunities.
PureHealth concluded the 2024 financial year with an exceptionally strong financial performance, underscored by revenues of AED25.8 billion, EBITDA of AED4.1 billion, and a net profit of AED1.7 billion.
Bolstered by a substantial cash position of AED11.9 billion and maintaining an impressively low leverage ratio of approximately 0.1x, the group’s balance sheet provides ample strategic flexibility.
Read: Why the UAE is the next big medical tourism destination
Group expands global operations
Operating within a resilient sector, PureHealth’s robust financial footing positions it comfortably to pursue its ambitious growth and acquisition agenda, further solidifying its status as a prominent healthcare group in the region and beyond.
As part of its continued growth, PureHealth recently acquired a 60 percent stake in Hellenic Healthcare Group from the global private equity firm CVC, which will remain as a minority partner alongside PureHealth within the acquired entity. The group remains focused on expanding its presence and capabilities to drive excellence across its global operations.
The proposed dividend marks a key milestone in PureHealth’s journey as a publicly listed entity, reflecting its strong financial standing and commitment to delivering shareholder value. Pending approval at the AGM, the dividend distribution will demonstrate the group’s ability to generate returns and create value for shareholders.
